Tilray Brands, Inc. (NASDAQ:TLRY) Receives $11.00 Consensus Target Price from Brokerages

Posted by Brenda Bartman on Aug 15th, 2026

Tilray Brands, Inc. (NASDAQ:TLRY – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eight research firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $11.00.

Several equities analysts have commented on TLRY shares. Wall Street Zen lowered shares of Tilray Brands from a “hold” rating to a “sell” rating in a report on Saturday, August 1st. TD Securities upgraded shares of Tilray Brands to a “strong-buy” rating in a research report on Friday, July 31st. TD Cowen cut their target price on Tilray Brands from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, July 14th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tilray Brands in a report on Friday, August 7th.

Check Out Our Latest Research Report on TLRY

Insider Activity at Tilray Brands

In other Tilray Brands news, CFO Carl A. Merton acquired 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The stock was acquired at an average cost of $4.62 per share, for a total transaction of $46,200.00. Following the transaction, the chief financial officer directly owned 139,753 shares in the company, valued at $645,658.86. This represents a 7.71% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Over the last ninety days, insiders acquired 15,000 shares of company stock worth $69,225. 0.84% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Jupiter Topco LLC bought a new stake in shares of Tilray Brands during the 2nd quarter valued at approximately $188,000. Hsbc Holdings PLC acquired a new stake in Tilray Brands in the second quarter valued at approximately $182,000. Legal & General Group Plc acquired a new stake in Tilray Brands in the second quarter valued at approximately $381,000. Ieq Capital LLC bought a new stake in shares of Tilray Brands during the second quarter worth $146,000. Finally, BlackRock Inc. bought a new stake in shares of Tilray Brands during the second quarter worth $2,073,000. Institutional investors and hedge funds own 9.35% of the company’s stock.

Tilray Brands Price Performance

Shares of NASDAQ TLRY opened at $4.67 on Friday. The stock has a market capitalization of $636.07 million, a PE ratio of -4.32 and a beta of 1.90. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.21 and a quick ratio of 1.37. The business has a fifty day moving average price of $4.52 and a two-hundred day moving average price of $5.93. Tilray Brands has a fifty-two week low of $3.67 and a fifty-two week high of $23.20.

Tilray Brands (NASDAQ:TLRY – Get Free Report) last issued its quarterly earnings results on Tuesday, July 28th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.42). Tilray Brands had a negative return on equity of 7.76% and a negative net margin of 13.11%.The company had revenue of $281.71 million during the quarter, compared to the consensus estimate of $246.30 million. As a group, equities analysts predict that Tilray Brands will post -0.4 earnings per share for the current fiscal year.

About Tilray Brands

(Get Free Report)

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.